1 WHY DID MONGOLIA’S PRESIDENT VISIT FINLAND? WWW.THEDIPLOMAT.COM PUBLISHED:2026/11/16      2 MONGOLIA–EU TRADE AND INVESTMENT SUBCOMMITTEE HOLDS MEETING WWW.MONTSAME.MN PUBLISHED:2026/11/16      3 MONGOLIA EXPECTS TO WELCOME ONE MILLIONTH TOURIST IN NOVEMBER WWW.MONTSAME.MN PUBLISHED:2026/11/16      4 MONGOLIA INVITES NORTH AMERICAN TRAVELERS TO DISCOVER THE 'BIG FIVE' OF THE STEPPE AND GOBI WWW.EINPRESSWIRE.COM PUBLISHED:2026/11/16      5 EXPERT EXPLAINS MINSK’S POLICY IN NON-CIS COUNTRIES USING MONGOLIA AS EXAMPLE WWW.ENG.BELTA.BY PUBLISHED:2026/11/16      6 UP TO 20,000 TONNES OF MEAT TO BE STOCKPILED FOR ULAANBAATAR’S WINTER AND SPRING DEMAND WWW.MONTSAME.MN PUBLISHED:2026/11/16      7 DAMAGE ASSESSMENT REPORT ON NUMRUG STRICTLY PROTECTED AREA PRESENTED WWW.MONTSAME.MN PUBLISHED:2026/11/16      8 NICOLAS CAGE PAID $276,000 FOR A DINOSAUR SKULL AFTER A BIDDING WAR WITH LEONARDO DICAPRIO, BUT IT TURNED OUT TO BE STOLEN WWW.CRONISTA.COM PUBLISHED:2026/11/15      9 MONGOLIA’S OIL REFINERY SCHEDULED TO BEGIN OPERATIONS IN FEBRUARY 2028 WWW.GOGO.MN PUBLISHED:2026/11/15      10 MONGOLIA ONCE AGAIN CALLS ON MALAYSIA TO DELIVER JUSTICE FOR ALTANTUYA WWW.ASIANEWS.IT PUBLISHED:2026/11/15      ТӨСВИЙН АЛДАГДАЛ ЖИЛИЙН ТӨЛӨВЛӨГӨӨНӨӨС 44 ХУВИАР ДАВЖ, 1.4 ИХ НАЯДАД ХҮРЛЭЭ WWW.ITOIM.MN НИЙТЭЛСЭН:2026/11/16     Д.БАТЛУТЫГ ЭНЭ 7 ХОНОГТ АЛБАН ЁСООР ЧӨЛӨӨЛЖ, ДАРААГИЙН САЙДЫГ ТОМИЛНО WWW.ITOIM.MN НИЙТЭЛСЭН:2026/11/16     НҮҮРСНИЙ ГАЛТ ТЭРЭГ ХОТЫН ТӨВӨӨР ЯВАХАА БОЛИНО WWW.ITOIM.MN НИЙТЭЛСЭН:2026/11/16     МОНГОЛ УЛС НЭГ САЯ ДАХЬ ЖУУЛЧНАА ЭНЭ САРЫН СҮҮЛЭЭР ХҮЛЭЭН АВНА WWW.EAGLE.MN НИЙТЭЛСЭН:2026/11/16     СЭЛБЭ ХОТХОНЫГ ДУЛААНААР ХАНГАЖ ЭХЭЛЖЭЭ WWW.NEWS.MN НИЙТЭЛСЭН:2026/11/16     ОЮУТОЛГОЙН АШГААС ИРГЭН БҮРТ 857 МЯНГАН ТӨГРӨГ ШИЛЖҮҮЛЭХ ЭСЭХИЙГ ХЭЛЭЛЦЭНЭ WWW.NEWS.MN НИЙТЭЛСЭН:2026/11/16     ХҮННҮГИЙН ҮЕИЙН ХАМГИЙН ТОМ БУНХНЫ МАЛТЛАГА ДУУСЖЭЭ WWW.MONTSAME.MN НИЙТЭЛСЭН:2026/11/15     НӨМРӨГИЙН ДЦГ-Т ГАРСАН ТҮЙМРИЙН ХОХИРЛЫН ҮНЭЛГЭЭНИЙ ТАЙЛАНГ БОУАӨЯ-НД ТАНИЛЦУУЛЖ БАЙНА WWW.IKON.MN НИЙТЭЛСЭН:2026/11/15     ЭГИЙН ГОЛЫН УСАН ЦАХИЛГААН СТАНЦ ТӨСЛИЙГ БАЙГАЛЬ ОРЧИНД СӨРӨГ НӨЛӨӨГҮЙ ХЭРЭГЖҮҮЛЭХ БОЛОМЖТОЙ ГЭСЭН УРЬДЧИЛСАН ДҮГНЭЛТ ГАРЧЭЭ WWW.EAGLE.MN НИЙТЭЛСЭН:2026/11/15     З.МЭНДСАЙХАН: ИРЭХ ОНЫ ТӨСВИЙН ОРЛОГЫГ УУЛ УУРХАЙН САЛБАР ДЭЭР ТУЛГУУРЛАЖ ОЛНО WWW.ITOIM.MN НИЙТЭЛСЭН:2026/11/14    
Англи амин дэм Монгол улсад албан ёсоор бүртгэгдлээ.

Johnson & Johnson's one-shot COVID-19 vaccine effective and safe: FDA staff www.reuters.com

(Reuters) - Johnson & Johnson’s one-shot COVID-19 vaccine appeared safe and effective in trials, U.S. Food and Drug Administration (FDA) staff said in documents published on Wednesday, paving the way for its approval for emergency use.
Slideshow ( 2 images )
The FDA’s panel of independent experts meets on Friday to decide whether to approve the shot. While it is not bound to follow the advice of its experts, the FDA usually does and has authorized vaccines from Pfizer and Moderna.
J&J said in documents submitted to the FDA that its data suggested its vaccine was effective at preventing asymptomatic infections. It said that in a preliminary analysis of its trial, it found 16 cases of asymptomatic cases in the placebo group versus two in the vaccine group, or an 88% efficacy rate.
While asymptomatic infection was not the primary goal of the trial, which studied the vaccine’s ability to stop moderate to severe COVID-19, the reduction of asymptomatic cases implies the shot can also cut transmission of the disease.
J&J’s vaccine was 66% effective in preventing COVID-19 against multiple variants in a global trial involving nearly 44,000 people, the company said last month.
Its effectiveness varied from 72% in the United States to 66% in Latin America and 57% in South Africa, where a new variant has spread, though the vaccine was 85% effective overall in stopping severe cases of the disease.
The vaccine was effective in reducing the risk of COVID-19 and preventing PCR-test confirmed COVID-19 at least 14 days after vaccination, the FDA said in its briefing documents.
Fourteen days after injection, only two vaccine recipients developed COVID-19 severe enough to need medical intervention, compared with 14 in the placebo group. After 28 days, no vaccine recipients developed COVID severe enough to require medical intervention whereas seven in the placebo group did.
Three vaccine recipients had severe side effects in the trial that were likely related to the vaccine, but the FDA said its analysis did not raise any specific safety concerns that would preclude issuance of an emergency use authorization.
The FDA said the most common solicited adverse reactions were injection site pain at 48.6%, headache at 39%, fatigue at 38.2% and myalgia at 33.2%. Other side effects included a fever in 9% of participants and a high fever in 0.2% of those who received the vaccine.
The regulator said one case of pericarditis, a heart disease, may have been caused by the vaccine. It said cases of a rare disorder, Guillain-Barre Syndrome, were unlikely to be related to the shot though data was insufficient to determine whether or not the vaccine had caused these side effects.
J&J had not previously released details of its clinical trial data beyond efficacy rates.
Reporting by Manas Mishra in Bengaluru; Mike Erman, Caroline Humer and Rebecca Spalding; Editing by Bernard Orr and David Clarke


Published Date:2021-02-24